Translate
Subscribe to Blog via Email
Ronny Allan
What are Gastric NENs
Unlike other anatomical types, the word Gastric is used to indicate a tumour (NET) or carcinoma (NEC) in the stomach. The stomach lies at the bottom of your oesophagus and connects to the first part of the small intestine (the duodenum). Clearly a key part of the gastrointestinal system, it processes food on its journey downwards.
The stomach produces strong acid. This kills many microorganisms that might have been swallowed along with the food. It also contains special chemicals called enzymes. These are important for breaking down the food so it can be absorbed by the body. After it leaves the stomach, the partially digested food passed into the intestines where it begins to be absorbed.
The main parts of the stomach are shown below (often this can give clues about the type):
Epidemiology
Gastric neuroendocrine neoplasms (gNENs) are not as common as most other types of NET with multiple observational studies showing that they account for approximately 8% of all digestive NENs and less than 1% of all gastric neoplasms. However, the incidence of gNENs has increased in most countries over recent decades, in part because of greater awareness of the disease among clinicians, improved diagnostic techniques and more widespread use of upper gastrointestinal endoscopy. Percentages by type are given below where known. Mixed Cell tumours, i.e. Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MINEN) are possible.
General point about gastric polyps. Gastric polyps are often found incidentally on endoscopy. A one-year study conducted in the United States on 120,000 patients showed a 6% prevalence of gastric polyps found on upper endoscopy. About 70% to 90%, are hyperplastic polyps or fundic polyps. Hyperplastic polyps are asymptomatic, found incidentally, rarely carry malignant risk, and occur in the setting of chronic inflammatory conditions or H. pylori infection. In the United States and other western countries, fundic gland polyps are most common due to proton pump inhibitor (PPI) use (see below) and low prevalence of H. pylori infection. These also are unlikely to progress to malignancy. Only a biopsy can confirm if a polyp is a NEN.
Types of Gastric NENs
Like many parts of the anatomy, NENs are categorised due to their heterogenous nature. Currently there are 3 main types of gNENs ranging from indolent types up to a type with the potential to be particularly very aggressive. I will also mention a fourth type which is starting to appear in many articles. The types are not always correlated with stage or grade.
Type I
Comprising between 70 and 80% of all Gastric NENs, type I tends to be confined to the stomach and act in an indolent manner. Can present with single or multiple tumours normally less than 1cm in size are polypoid or submucosal growths.
They are heavily associated with Chronic atrophic gastritis (CAG), Autoimmune CAG, pernicious anaemia (an autoimmune or genetic condition) and achlorhydria (a condition in which the stomach does not produce hydrochloric acid).
Type I gNETs occur in response to hypergastrinemia (elevated fasting serum gastrin levels) in the setting of achlorhydria (gastric pH > 4) typically seen in autoimmune CAG where gastric parietal cells in the gastric body and fundus are destroyed by an autoimmune process.
Mainly found in the body and fundus. Risks of metastases very low at between 2 and 5%.
Type II
Comprising between 5 and 10% of all Gastric NETs and much misunderstood within the NET community. This type also presents in a setting of hypergastrinemia (elevated fasting serum gastrin levels) but unlike Type I, with hyperchlorhydria (gastric pH ≤ 2) and hypertrophic mucosa. Can present often with multiple tumours normally less than 2cm in size.
However, in a Type II gNET, the excessive gastrin is being released from a secondary source such as from a gastrinoma in the pancreas or duodenum (Zollinger-Ellison syndrome), i.e. an existing NET. They are often associated with MEN1, rarely with sporadic ZES.
Type II gNETs are mainly found in the body, fundus and antrum of the stomach. Risk of metastases is much higher than type I with between 10 and 30% chance, so generally still a good outlook.
Type III
These are heterogenous type of gNEN which can occur sporadically and in large single tumours greater than 2cm. They are normally not related to hypergastrinemia or achlorhydria/hyperchlorhydria with normal levels of Gastrin and pH. Their heterogeneity means they can be any of the 3 well differentiated NET grades or a Neuroendocrine Carcinoma (NEC) which is poorly differentiated by default. Most type III are, however, grade 3. The risk of metastases is high between 50 and 100%.
Gastric Neuroendocrine Carcinoma (i.e. poorly differentiated)
These are rarely found but are very aggressive and treated similar to other Neuroendocrine Carcinomas. They can be small or large cell.
Type IV Proposals
In addition to these classical three subtypes, the existence of a type IV gNEN has been suggested.
One proposition has been that this fourth type has similar characteristics to type III gNENs, but an even more aggressive nature. This type of gNEN may arise from other types of endocrine cells and be a poorly differentiated NEC. In modern NEN classification systems, however, it is likely that this type of type IV gNEN simply represents a type III gNEN which has features of a NEC rather than a NET.
A second different proposal for a type IV gNEN involves a gNEN that has developed in a patient who has an intrinsic defect in the secretion of acid by gastric parietal cells. This type of type IV gNEN is characterised by hypochlorhydria, hypergastrinaemia and multiple small gastric polyps (similar to type I), but histological examination of the gastric corpus mucosa classically reveals hypertrophy and hyperplasia of parietal cells, with a vacuolated cytoplasm suggesting a structural abnormality that prevents acid secretion. This type of gNEN is very rare, and the mechanism of pathogenesis is similar to type I, so it is not frequently included as a separate entity in gNEN classification systems.
What is Gastrin?
Gastrin is a hormone secreted by G cells in the stomach lining. At physiological concentrations, gastrin controls gastric acid production, and repairs and maintains the stomach lining.
When we eat food, G cells release gastrin into the bloodstream. Gastrin stimulates gastrin receptors (also called CCK2 receptors, CCK2 R) on enterochromaffin-like (ECL) cells in the stomach lining to release histamine, which in turn stimulates histamine H2-receptors (H2R) on adjacent parietal cells (acid-producing cells) to secrete acid into the stomach via the proton pump in the parietal cells. As acid rises, and food passes out of the stomach, it switches on D cells in the stomach lining to release another hormone, somatostatin, which enters the bloodstream and switches off gastrin production by the G cells
What is Hypergastrinemia?
Anything that reduces gastric acid production (hypoacidity) results in persistently increased blood levels of gastrin (hypergastrinemia), which leads to: irregular gene expression in cells of the stomach lining; increased growth of those cells and their potential to metastasise (spread); and reduced apoptosis (natural cell death). All of those effects increase the risk of malignancy.
The main causes of hypoacidity and hypergastrinemia are:
- Autoimmune chronic atrophic gastritis (CAG), a condition in which patients make antibodies against their parietal cells. Hypergastrinaemia causes growth of ECL cells and, in some patients, formation of multiple gastric neuroendocrine tumours (gNETs).
- Inflammation of the stomach lining by infection with H. pylori bacteria. A study in an animal model has shown that hypergastrinaemia is the cause of the inflammation. H. pylori is also the main cause of stomach ulcers and gastric cancer.
- Medicines that suppress acid production, such as a proton pump inhibitor (PPI) or potassium-competitive acid inhibitor and are mainly used to treat heartburn and indigestion caused by backflow of acid (reflux) from the stomach into the oesophagus (gullet).
What is Pernicious anemia?
Pernicious anemia occurs when your body can’t absorb enough vitamin B12 to function properly. This type of anemia is called “pernicious” because it was once considered a deadly disease. Today, though, it’s relatively easy to treat. While vitamin B12 deficiency anemia may be caused by a lack of vitamin B12 in the diet, pernicious anemia is caused by an inability to absorb vitamin B12. Pernicious anemia can be autoimmune or genetic related.
Syndromes and Gastric NENs
So called ‘carcinoid syndrome‘ is rare in gNENs and any clinical manifestation is atypical consisting exclusively of redness due to histamine production. Diarrhea can be a symptom of hypergastrinemia.
Hypoacidity and hypergastrinemia are not carcinoid syndrome, the causes of those symptoms are listed above.
Type II gNET are a secondary effect of excessive gastrin is being released from a secondary source such as a gastrinoma in the pancreas or duodenum i.e. an existing NET outside the stomach. This existing NET is related to a syndrome known as Zollinger-Ellison syndrome. Gastrinomas are frequently associated with MEN1, a hereditary NET syndrome.
Hereditary connections
Nothing observed other than the relationship with Type II and MEN1 already covered under Type II.
Treatment and Surveillance
The treatment of gNETs depends on the clinical type, disease extent, the differentiation of the lesion and the presence or absence of poor prognostic factors.
This differs from regional/national guidelines but in general:
Type I gNETs will normally be managed via gastroscopy surveillance with polyp removal when necessary. B12 supplementation and treatment for iron deficiency anaemia and pernicious anaemia may be necessary.
Type II gNETs may already have a management system in place for the Gastrinoma and where applicable for MEN1. If the Gastrinoma is considered a causal factor in the gNET, surgery may be considered to remove the Gastrinoma. Endoscopic resection of gastric polyps with gastroscopy surveillance is normally sufficient if no other prognostic factors are present.
Type III gNENs may need more aggressive treatment including surgery and chemotherapy where applicable.
So called ‘carcinoid syndrome‘ is rare in gNENs and any clinical manifestation is atypical consisting exclusively of redness due to histamine production.
The use of somatostatin analogues (SSA) for localised gNENs is generally not required although some Type II gNETs may already be established on SSAs. Guidelines say they should be considered in metastatic cases and for Type II gNET if not already established.
What are Proton Pump Inhibitors?
Proton pump inhibitors (PPIs) are among the most commonly used medications in the world. They reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid. Acid is necessary for the formation of most ulcers in the oesophagus, stomach, and duodenum, and the reduction of acid with PPIs prevents ulcers and allows any ulcers that exist in the oesophagus, stomach, and duodenum to heal. PPIs are prescribed to treat acid-related conditions such as:
- Esophageal, duodenal and stomach ulcers
- NSAID-associated ulcer
- Ulcers
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison Syndrome – ZES (note this is a syndrome associated with a functioning duodenal or pancreatic NET known as a Gastrinoma)
- They also are used in combination with antibiotics for eradicating Helicobacter pylori, a bacterium that together with acid causes ulcers of the stomach and duodenum for eradicating H. pylori, a bacterium that together with acid causes ulcers of the stomach and duodenum.
The PPI connection
This continues to be a controversial area. It is already well known that PPI use causes elevation of the gold standard NEN tumour marker Chromogranin A to the point that many doctors no longer use this test. There are several other potential causes of elevation but PPI is the most common given its wide use in the general population.
More controversial is the suggestion that hypergastrinemia exerts a proliferative effect on ECL-cells in the stomach, leading to linear and micronodular ECL-cell hyperplasia and subsequently dysplasia and NET development. In the hypoacidic stomach of patients with autoimmune chronic atrophic gastritis (CAG) or mutations of genes controlling acid production, somatostatin production by D cells is not switched on and gastrin production by G cells continues. Hypergastrinemia ensues and causes ECL-cell growth and, in some patients, gNETs, which can be seen at gastroscopy. Although PPIs also reduce acid production and cause hypergastrinemia, there are only a few case reports of gNETs in patients on long-term PPI therapy.
Two add-on points.
One NET clinic has suggested that those taking PPI could be just as well served by migration to Histamine H2 Receptor Antagonists (H2RA) that reduce the amount of acid produced by the cells in the lining of the stomach. They are also commonly called H2 blockers. This includes a tapering off timeline given the adverse effect of suddenly stopping PPI use. You can read about a suggested migration strategy by clicking here. You should NEVER stop taking PPIs without speaking to the doctor who prescribed them.
According to UKINETs, Type I Gastric NETs should preferably stop PPIs as continued use will further increase gastrin and little rationale for ongoing treatment. You should NEVER stop taking PPIs without speaking to the doctor who prescribed them.
Guidelines
There are numerous clinical practice guidelines on management of gNETs where management of these tumours is stratified according to risk of locoregional and distant metastasis. NCCN and ENETS cited below.
NCCN
Most small gNETs can be removed with curative intent with only endoscopic surveillance going forward (Reference 6). If “invasive”, surveillance using conventional imaging (e.g. CT/MRI) can be used with more frequent checks in the short and long term (Reference 6 – page NET-8). Treatments are factored in if either functional or non-functional. (Reference 6 – Page NET-5). Metastatic cases may require additional treatment (e.g. somatostatin analogues and targeted therapies; and wider surveillance (Reference 6 – page NET-9).
ENETS
Guidance for gNETs has recently been reinforced by the publication of revised guidelines in 2023. Read more here or click on the picture
NEC/MiNEN
Guidelines for gNEC and MiNEN involving duodenum will be similar to other NEC and MiNEN. To follow.
Resources
- Exarchou, K., Stephens, N.A., Moore, A.R. et al. New Developments in Gastric Neuroendocrine Neoplasms. Curr Oncol Rep 24, 77–88 (2022). https://doi.org/10.1007/s11912-021-01175-y
- McCarthy DM. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship? Int J Mol Sci. 2020 Jan 19;21(2):662. doi: 10.3390/ijms21020662. PMID: 31963924; PMCID: PMC7014182.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Neuroendocrine and Adrenal Tumors Version 2.2022 — December 21, 2022
- UKINETS Clinical Practice Management of patients with Gastric Neuroendocrine Neoplasm
- European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastric neuroendocrine tumours (NETs) G1–G3 (ronnyallan.net)
Clinical Trial Drug
Phase 2 clinical trials took place in several countries including UK and Norway. The manufacture is looking to launch a Phase 3 clinical trial with over 200 participants on an international basis. Read more here or by clicking on the graphic.
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Personal Facebook. Like this page please.
Blog Facebook. Like this page please.
Awareness Facebook Like this page please.
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Digestive Neuroendocrine Carcinoma
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based
Neuroendocrine Cancer – Clinical Esoterica
One of the key awareness messages for Neuroendocrine Cancer is the hormonal syndromes that can often accompany the diagnosis for many people. As it’s a
Neuroendocrine Cancer – The F Words
When I first created my blog in April 2014, I had to find some material to lead up to my 84 mile walk (at the
Laughter is the best medicine
Laughter is important. This is a remastered version of one of my early blog posts. It centred on a ‘get-well’ card I received recuperating in
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastric neuroendocrine tumours (NETs) G1–G3
The ENETS 2023 guideline for gNETs are combined with the guidelines for Duodenal NET (dNET) due to their close relationship in anatomical terms. Gastric neuroendocrine
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Duodenal neuroendocrine tumours (NETs) G1–G3
The ENETS 2023 guideline for dNETs are combined with the guidelines for Gastric NET (gNET) due to their close relationship in anatomical terms. But there
I woke up on World Neuroendocrine Cancer Day
1 year after 2 x surgery Macmillan Cancer Support featured this post CKN featured this post 5 years after 3 surgeries 10 years after surgery
Piss off Cancer, it’s been 13 years since my “big surgery”
D Day I was 54 years and 9 months old at diagnosis on 26th July 2010. For the first few months, I had no idea
When Should Genetic Testing Be Performed in Patients With Neuroendocrine Tumors?
Another episode in the expert opinion series. I thought this might be useful for some of you after an interesting ‘google alert’ brought up these
A cup of tea
I would also mention those who contributed to my “Tea Fund” which resides on PayPal. You don’t need a PayPal account as you can select a card but don’t forget to select the number of units first (i.e. 1 = £4, 2 = £8, 3 = £12, and so on), plus further on, tick a button to NOT create a PayPal account if you don’t need one. Clearly, if you have a PayPal account, the process is much simpler
Through your generosity, I am able to keep my sites running and provide various services for you. I have some ideas for 2023 but they are not detailed enough to make announcements yet.
This screenshot is from every single post on my website and depending on which machine you are using, it will either be top right of the post or at the bottom (my posts are often long, so scroll down!)
Hi Ronny, thanks for this article, much appreciated – would it be ok to print a copy to give to my GP?
I have gastric NETs type 1, but I also have atypical carcinoid syndrome, proven recently by a prolonged episode of carcinoid syndrome on cessation off my prophylactic IV meds 12 hours after surgery; this meant I required 4 sub cut sandostation injections over 24 hours before it abated. Prior to this my specialist suspected it but now it is proven of course and I carry a I.C.E letter with me at all times. My specialist, as you’ve said in the article, has told me it is rare, and that he doesn’t know why I have it. I’ve read a few articles about it but they are thin on the ground.
Thank you for highlighting this rare possibility as most GP’s know very little about GNETs (or any other NETs for that matter) or carcinoid syndrome, but this article would help my GP to know a little more about my situation, especially from the atypical carcinoid syndrome standpoint.
Interestingly I was put on high strength PPI’s by my GP (14 years ago) for at least 3 – 4 years, my husband and I eventually worked out that they were making me very ill indeed – I couldn’t eat, couldn’t excrete food or even drink much by the end when I was hospitalised.
I diagnosed GNet’s myself through reading articles and insisting on a second gastroscopy because of the histology report findings on the first gastroscopy – I was finally diagnosed 5 years ago and my specialist congratulated me on my research and for catching them (GNETs) early.
I can’t thank you enough for this article.
Yes, but once printed, it will become out if date. I’m always tweaking my blogs.
(But you won’t find a better summary 🙂)